Despite the wide recommendation and clinical use of anti-VEGF treatment for AMD patients, the main reported disadvantage associated with this therapy is mainly related to the short half-life of the anti-VEGF molecules, and the consequent demand for repeated injections [20,21]. This evidence concerns the gene VEGFA and age-related macular degeneration.